[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"ketogenic-diet\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:ketogenic-diet":30},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,53,82,106],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":20,"enrollmentInfo":21,"targetDuration":4,"studyType":24,"phases":25,"briefSummary":27,"conditions":28,"keywords":33,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":41,"lastUpdatePostDateStruct":42,"startDateStruct":45,"completionDateStruct":47,"leadSponsor":49,"locationsCount":52},"100644813","dietary-macronutrients-and-gut-microbiota-inflammation-and-metabolic-markers-100644813",false,"NCT07672691","Dietary Macronutrients and Gut Microbiota, Inflammation, and Metabolic Markers","Effects of Diets Differing in Macronutrient Composition on Gut Microbiota Composition, Intestinal Inflammation Markers, Gene Expression Profiles, and Blood Biochemical Parameters in Diverse Populations.","DIETMICRO","Inclusion Criteria:\n\nIn addition to the physical activity requirements described above, the study will include men and women aged 18-60 years with:\n\nBMI not exceeding 40kg\u002Fm²\n\nHabitual mixed diet prior to study enrollment\n\nNormal blood pressure\n\n* Exclusion Criteria:\n\nPoprawiłem już \\*\\*Exclusion Criteria\\*\\* w poprzedniej odpowiedzi - wszystkie te kryteria już tam są wpisane. Oto pełna, ostateczna wersja z wszystkimi wskazanymi kryteriami wyłączenia:\n\n\\*\\*\\* \\*\\*Exclusion Criteria:\\*\\*\n\n* Use of medications regulating \\*\\*glucose levels\\*\\* (e.g., metformin) or \\*\\*blood lipids\\*\\* (e.g., \\*\\*statins\\*\\*)\n* \\*\\*Hypertension\\*\\* or pharmacological treatment for hypertension\n* Diagnosed \\*\\*gastrointestinal disorders\\*\\*, including:\n* Gastric and duodenal ulcers\n* \\*\\*Irritable bowel syndrome (IBS)\\*\\*\n* \\*\\*Ulcerative colitis\\*\\*\n* \\*\\*Celiac disease\\*\\*\n* Chronic use of medications such as:\n* \\*\\*Mesalazine\\*\\*\n* \\*\\*Corticosteroids\\*\\*\n* \\*\\*Statins\\*\\*\n* \\*\\*Proton pump inhibitors (PPI)\\*\\*\n* \\*\\*Non-steroidal anti-inflammatory drugs (NSAIDs)\\*\\*\n* \\*\\*Anticonceptional medications\\*\\*\n* \\*\\*Any supplements\\*\\*\n* \\*\\*Alcohol consumption\\*\\* \\> 2 times\u002Fweek with \\> 15 g alcohol per occasion (approximately 15 g alcohol = 330 mL beer, 150 mL dry red wine, or 50 mL vodka)\n* \\*\\*Smoking cigarettes\\*\\*\n* Following a \\*\\*ketogenic diet\\*\\* or \\*\\*vegetarian diet\\*\\* within \\*\\*1 month\\*\\* prior to study enrollment",true,"ALL","18 Years","60 Years",{"count":22,"type":23},200,"ESTIMATED","INTERVENTIONAL",[26],"NA","Poniżej znajduje się bardziej płynna i mniej powtarzalna wersja tekstu:\n\nThis 12-week randomized controlled trial will investigate the effects of dietary patterns with different macronutrient compositions on gut microbiota, intestinal inflammation, gene expression, and metabolic health in healthy adults.\n\nParticipants will be randomly assigned to one of three dietary interventions: a ketogenic diet (KD), a vegetarian diet (VD), or a control diet (CD) reflecting their habitual mixed dietary pattern. Adherence to the assigned diet will be monitored through dietary records and regular nutritional counseling.\n\nThe study will evaluate changes in gut microbiota composition, inflammatory biomarkers, transcriptomic profiles, and blood biochemical parameters associated with lipid and glucose metabolism. Blood and stool samples will be collected at predefined time points throughout the intervention, while participants in the KD group will additionally undergo ketone monitoring to assess dietary compliance.\n\nBy comparing the ketogenic and vegetarian diets with a standard mixed diet, this study aims to determine their effects on gut health, metabolic function, and systemic inflammation, thereby providing evidence to inform dietary recommendations.\n\nTa wersja eliminuje powtórzenia (\"diet\", \"study\", \"monitor\", \"effects\"), jest bardziej naturalna stylistycznie i odpowiada standardowi językowemu publikacji w czasopismach z zakresu żywienia i medycyny.",[29,30,31,32],"Nutrition","Ketogenic Diet","Gene Expression","Diet",[34,35,36,37,38,39],"ketogenic diet","gene expression","transcriptomics","biochemical parameters","stool microbiome","ketone bodies","RECRUITING","2026-07-01",{"date":43,"type":44},"2026-07-02","ACTUAL",{"date":46,"type":44},"2024-09-02",{"date":48,"type":23},"2028-12-30",{"name":50,"class":51},"The Jerzy Kukuczka Academy of Physical Education in Katowice","OTHER",2,{"id":54,"slug":55,"hasResults":11,"nctId":56,"briefTitle":57,"officialTitle":57,"acronym":4,"eligibilityCriteria":58,"healthyVolunteers":17,"sex":18,"minAge":59,"maxAge":60,"enrollmentInfo":61,"targetDuration":4,"studyType":24,"phases":63,"briefSummary":64,"conditions":65,"keywords":70,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":72,"lastUpdatePostDateStruct":73,"startDateStruct":75,"completionDateStruct":77,"leadSponsor":79,"locationsCount":81},"100640797","effects-of-ketogenic-diet-on-alcohol-intoxication-100640797","NCT07602270","Effects of Ketogenic Diet on Alcohol Intoxication","Inclusion Criteria:\n\n1. Age 21 years to 50 years old.\n2. Willingness to provide signed, informed consent and commit to completing study procedures. Reported on at least one day in the month prior to consent of consuming 2 or more standard alcohol drinks on a single day.\n\nExclusion Criteria:\n\n1. Unwilling or unable to refrain from use, within 24 hours of the alcohol lab procedures, psychoactive medications or medication that may affect study results.\n2. Current DSM-5 diagnosis of any major psychiatric disorder (other than nicotine use disorders, or marijuana use disorders) as identified by clinical examination or structured interview that could interfere with study participation or make it hazardous for the subject.\n3. Currently taking medication(s) that could interfere with study participation or make it hazardous for the subject to participate. (e.g. anticholinergics; antipsychotics; lithium; psychotropic drugs not otherwise specified)\n4. Positive urine drug screen, positive for all substances but marijuana at screening or study visits (may be repeated once and if the result is negative on repeat, it is not exclusionary).\n5. A current, clinically significant physical disease or abnormality on the basis of medical history, or routine laboratory evaluation that can impact brain function, the use of a ketone supplement, administration of ketogenic diet, or the use of alcohol (e.g., epilepsy, diabetes, irritable bowel syndrome, Crohn's disease, liver disease, kidney disease, kidney stones, chronic metabolic acidosis or a cardiomyopathy as determined by history and clinical exam).\n6. Currently suffering from or has a history of stroke and\u002For stroke related spasticity.\n7. Head trauma with loss of consciousness for more than 30 minutes or associated with skull fracture, inter-cranial bleeding or abnormal MRI (self-report, medical history).\n8. Weight greater than 225lbs (Need to cap amount of alcohol given based on weight to individuals).\n9. Females who are pregnant or breast-feeding\n10. Contraindication to MRI, including presence of ferromagnetic objects, claustrophobia or fear of enclosed, medical conditions that prevent subjects from lying comfortably flat on his\u002F her back for up to 2 hrs.","21 Years","50 Years",{"count":62,"type":23},20,[26],"The research study is being conducted to better understand the effects of ketosis on brain functioning and the acute effects of alcohol. Participants will be asked to undergo \\~4 weeks of ketogenic diet intervention. The study involves three lab visits: Lab 1 before starting the diet, Lab 2 after about 2 weeks after starting the diet, and Lab 3 after being on the diet for 4 weeks. All of the labs will include an alcohol tolerance test, and blood draws. Lab 1 and Lab 3 will also include an Magnetic resonance imaging scan. Due to scheduling, study procedures at 2 and 4 weeks may occur +\u002F- 3 days. Magnetic resonance imaging (MRI) of the brain will measure levels of nicotinamide adenine dinucleotide (NAD) (a coenzyme that is important for energy metabolism), lactate (a metabolite produced during energy metabolism), and neurotransmitters glutamate and GABA. Alcohol tolerance will be tested using a dose of alcohol (approximately 4-5 alcohol beverages) to will elevate breath alcohol levels to approximately 0.08% to measure the acute effects of alcohol. Blood samples will be collected to measure varying metabolites.",[30,66,67,68,69],"Alcohol Drinking","Alcohol Use Disorder","Magnetic Resonance Imaging","Alcohol Intoxication",[30,71],"Alcohol tolerance test","2026-05-15",{"date":74,"type":44},"2026-05-22",{"date":76,"type":44},"2026-05-14",{"date":78,"type":23},"2030-05",{"name":80,"class":51},"University of Pennsylvania",1,{"id":83,"slug":84,"hasResults":11,"nctId":85,"briefTitle":86,"officialTitle":87,"acronym":88,"eligibilityCriteria":89,"healthyVolunteers":11,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":90,"targetDuration":4,"studyType":24,"phases":92,"briefSummary":93,"conditions":94,"keywords":4,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":97,"lastUpdatePostDateStruct":98,"startDateStruct":100,"completionDateStruct":102,"leadSponsor":104,"locationsCount":81},"100589090","ketogenic-diet-therapy-in-patients-with-acromegaly-100589090","NCT06949891","KETOgenic Diet Therapy in Patients With ACROmegaly","Ketogenic Diet Therapy in Patients With Acromegaly","KETOACRO","Inclusion Criteria:\n\n* Male or female, 18 years or older\n* Diagnosis of acromegaly based on elevated GH and\u002For IGF-I levels due to a pituitary tumor\n* IGF-I levels above 80% upper limit of the normal range (xULN)) on a stable medication dose for at least 4 months\n* Written informed consent\n\nExclusion Criteria:\n\n* Pregnancy or breastfeeding\n* Pegvisomant treatment\n* Has undergone pituitary surgery or radiotherapy within 6 months prior to s study entry;\n* It is anticipated that the patient will receive pituitary surgery or radiotherapy during the study;\n* History or presence of epilepsy;\n* Participation in a trail of an experimental drug or device within 30 days prior to screening;\n* Has a mental condition rendering the subject unable to understand the nature, scope and possible consequences of the study\n* Screening HbA1c \\> 6,5%;\n* Use of antidiabetic medication other than Metformin",{"count":91,"type":23},60,[26],"Acromegaly is caused by a tumour located at the base of the brain in the pituitary gland that produces too much growth hormone (GH). Symptoms caused by the excess of GH, and consequently increased insulin like growth factor 1 (IGF-1), are disproportionate growth of body parts, fluid retention, snoring and excessive perspiration. The various metabolic changes that occur due to acromegaly increase the risk for insulin resistance, diabetes mellitus, arterial hypertension, sleep apnoea and thus an increased risk of cardiovascular disease if left untreated. The result is signs and symptoms, increased mortality, morbidity, and greatly reduced quality of life (QoL). Normalisation of GH and IGF-1 gives a normalisation of mortality, however morbidity and QoL do not (completely) normalise. After surgery, a somatostatin analogue is the primary medical treatment, however, normalisation occurs in only 40% of patients.\n\nRecently, in a proof-of-principle study, the researchers showed that a 2-week ketogenic diet (low in carbohydrates) in patients with somatostatin analogues could significantly reduce IGF-1 values. Patients felt better and sometimes even needed less somatostatin analogues. This proof of concept led to the new hypothesis that acromegaly patients with somatostatin analogues should possibly be treated with a eucaloric low-carbohydrate ketogenic diet for a longer period of time to improve their biochemistry, symptoms and QoL. Additionally, this diet can make a significant contribution in the treatment of insulin resistance and glucose intolerance that often occur in this patient group.",[95,30,96],"Acromegaly Due to Pituitary Adenoma","Mediterranean Diet","2025-04-25",{"date":99,"type":44},"2025-04-29",{"date":101,"type":44},"2023-06-01",{"date":103,"type":23},"2028-05-01",{"name":105,"class":51},"Erasmus Medical Center",{"id":107,"slug":108,"hasResults":11,"nctId":109,"briefTitle":110,"officialTitle":111,"acronym":4,"eligibilityCriteria":112,"healthyVolunteers":11,"sex":18,"minAge":19,"maxAge":113,"enrollmentInfo":114,"targetDuration":4,"studyType":24,"phases":115,"briefSummary":118,"conditions":119,"keywords":122,"overallStatus":127,"whyStopped":4,"lastUpdateSubmitDate":128,"lastUpdatePostDateStruct":129,"startDateStruct":131,"completionDateStruct":133,"leadSponsor":135,"locationsCount":81},"100584991","phase-1-single-center-trial-on-ketogenic-diet-and-immunotherapy-in-advanced-cancer-this-study-evaluates-the-safety-and-effects-of-a-ketogenic-diet-kd-combined-with-immunotherapy-in-adults-with-advanced-melanoma-cscc-or-rcc-100584991","NCT06896552","Single-Center Trial on Ketogenic Diet and Immunotherapy in Advanced Cancer This Study Evaluates the Safety and Effects of a Ketogenic Diet (KD) Combined With Immunotherapy in Adults With Advanced Melanoma, cSCC, or RCC.","Investigating the Effect of Ketogenic Diet on Immunological Parameters in Advanced Cancer Patients Undergoing Immunotherapy","Inclusion Criteria:\n\n* • Males and females, age \\>= 18 years\n\n  * Patients with a histologically confirmed melanoma or cSCC or RCC receiving first line treatment with combination nivolumab and ipilimumab \u002Frelatlimab or single agent ipilimumab, nivolumab, pembrolizumab, Cemiplimab.\n  * Able to read, understand, and provide written informed consent\n  * Willing and able to complete all study-specific procedures and visits\n  * Patients with Eastern Cooperative Oncology Group (ECOG) performance status ≤2.\n  * Blood tests:\n\n    * Creatinine (Cr) \\\u003C 1.5 mg\u002FdL.\n    * Magnesium normal range ( 1.5 -2,6 mg\u002FdL)\n    * Liver function tests (LFTs) 2.5x upper limit of normal (ULN).\n    * Neutrophils ≥ 1,000\u002Fmm3, platelets ≥ 50,000\u002Fmm3, Hb\\>8 g\u002FdL\n    * Women of childbearing potential must have a negative β-HCG pregnancy test documented within 1 week of registration.\n\nExclusion Criteria:\n\n* • Individuals \\\u003C 18 years of age\n\n  * Unable or unwilling to provide consent\n  * Other active malignancy (other than adequately treated and cured basal or squamous cell skin cancer, curatively treated in situ disease, or any other cancer from which the patient has been disease free \\>=2 years)\n  * Currently consuming a low-carbohydrate (\\\u003C 130 g\u002Fday) or KD or done so in the last 6-months\n  * Patients currently participating in an interventional or therapeutic clinical trial involving the use of active anti-cancer therapy.\n  * Active autoimmune diseases requiring active Immune suppressive medications\n  * Systemic steroid therapy, excluding for replacement due to adrenal insufficiency\n  * Major surgery within last 3 months\n  * BMI \\\u003C18 or \\>35\n  * Medical contraindications to the intervention diet as determined by the treating physician.\n  * Self-reported major dietary restrictions related to the intervention such as irritable bowel syndrome (IBS).\n  * Patients with a history or active eating disorder\n  * Uncontrolled Diabetes mellitus or patients receiving insulin\n  * Known diagnosis of HIV\n  * Known active hepatitis B or hepatitis C\n  * Known inborn errors of lipid metabolism\n  * Sever or uncontrolled Hyperlipidemia (total cholesterol over 400 mg \u002F dL, low-density lipoprotein (LDL) above 300 mg \u002F dL, triglycerides over 500 mg \u002F dl.).\n  * Pregnant or lactating.\n  * Patients who have undergone a transplant","100 Years",{"count":91,"type":23},[116,117],"PHASE1","PHASE2","This clinical trial aims to evaluate whether a ketogenic diet (KD), when combined with immunotherapy, can improve immune function and treatment outcomes in patients with advanced melanoma, cutaneous squamous cell carcinoma (cSCC), or renal cell carcinoma (RCC).\n\nWhy Is This Study Important? Immunotherapy is a promising cancer treatment, but not all patients respond well. Research suggests that diet, particularly a high-fat, low-carbohydrate ketogenic diet, may help boost the immune system and make treatments more effective.\n\nWhat Will This Study Examine?\n\nResearchers want to understand:\n\nIs the ketogenic diet well-tolerated for cancer patients? Does the diet improve immune responses and treatment effectiveness?\n\nHow Will the Study Work?\n\nParticipants will be placed into one of two groups:\n\nKetogenic Diet (KD) Group: A structured high-fat, low-carb diet (intermittent schedule: 2 weeks on, 1 week off).\n\nStandard Diet (SD) Group: A typical diet with no major changes. Throughout the study, a dietitian will closely support and guide you. Both groups will continue their standard immunotherapy treatment.\n\nWhat Will Participants Do? Write their food intake three times a week to help assess dietary adherence Follow their assigned diet for 10 weeks Have weekly check-ins with a dietitian (in-person at the hospital or via phone) Have weekly blood glucose and ketone level checks using a home device. Provide monthly blood samples to measure immune response during routine immunotherapy infusions Provide stool samples for gut microbiome analysis at the start and end of the study Measure Monthly Weight, body composition, and resting calorie burn Complete quality-of-life questionnaires\n\nWhat Are the Potential Benefits? Improved response to immunotherapy Better understanding of how diet influences cancer treatment Potential for a new supportive strategy for cancer care\n\nThis study may help uncover ways to enhance cancer treatment through personalized nutrition.",[120,121,30],"Cancer","Immunotherapy",[123,124,30,125,126],"Metastatic Melanoma","Renal Cell Carcinoma","Dietary Intervention and Immunotherapy","Ketogenic diet (KD) and cancer treatment","NOT_YET_RECRUITING","2025-03-19",{"date":130,"type":44},"2025-03-26",{"date":132,"type":23},"2025-04",{"date":134,"type":23},"2027-04",{"name":136,"class":51},"Rabin Medical Center"]